10.6084/m9.figshare.c.3672697_D1.v1 Jae-Ho Yoon Jae-Ho Yoon Hee-Je Kim Hee-Je Kim Dae-Hun Kwak Dae-Hun Kwak Sung-Soo Park Sung-Soo Park Young-Woo Jeon Young-Woo Jeon Sung-Eun Lee Sung-Eun Lee Byung-Sik Cho Byung-Sik Cho Ki-Seong Eom Ki-Seong Eom Yoo-Jin Kim Yoo-Jin Kim Seok Lee Seok Lee Chang-Ki Min Chang-Ki Min Seok-Goo Cho Seok-Goo Cho Dong-Wook Kim Dong-Wook Kim Jong Lee Jong Lee Woo-Sung Min Woo-Sung Min Additional file 1: Table S1. of High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study Springer Nature 2017 Acute promyelocytic leukemia WT1 FLT3 mutation Minimal residual disease 2017-01-23 05:00:00 Journal contribution https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_Table_S1_of_High_WT1_expression_is_an_early_predictor_for_relapse_in_patients_with_acute_promyelocytic_leukemia_in_first_remission_with_negative_PML-RARa_after_anthracycline-based_chemotherapy_a_single-center_cohort_study/4580191 Multivariate analysis in APL patients with CMR. Figure S1. Consort diagram of enrolled patients in this study. Underlined patients were excluded in this study (n=25). Abbreviation: APL, acute promyelocytic leukemia; ATRA, all-trans retinoic acid; CR, complete remission, CMR, complete molecular response; WT1, Wilms tumor 1. Figure S2. Comparison of PML-RARa and WT1 expression levels between relapsed and non-relapsed patients from diagnosis to relapse or 1 year after starting maintenance for non-relapsed patients. (DOCX 152 kb)